Researchers at UT Southwestern Medical Center discovered that genetically modifying fat cells in obese mice to produce higher ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Biotech M&A is heating up, and Mirum Pharmaceuticals stands out. Discover why analysts predict a 50% upside and long-term ...

It was a landmark year for medical advancements in 2024, bringing a wave of innovative treatments that promise to reshape ...

Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, ...